Drugs / ART101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07614308 | Oct 2025 → Oct 2026 expected | hypertensive disorder | Arnatar Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06780033 | Mar → Apr 2025 | hypertensive disorder | Arnatar Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT07529600 | Jan 2024 → Dec 2025 | hypertensive disorder | Arnatar Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-29 | Arnatar Therapeutics, Inc. | Results Arnatar Therapeutics Presents Clinical Data from Healthy Volunteers at the American College of Cardiology Annual Scientific Session (ACC.26) arnatar.com ↗
In a first-in-human, randomized, placebo-controlled Phase 1 study in healthy subjects, ART101, a GalNAc-conjugated siRNA targeting hepaticangiotensinogen (AGT), demonstrated robust, dose-dependent, and durable target engagement. |
| 2025-06-20 | Archeus Technologies, Inc. | Regulatory Archeus Technologies Receives FDA Clearance of Investigational New Drug Application for ART-101 in Development for the Treatment of Prostate Cancer archeustech.com ↗
This IND clearance enables Archeus to initiate a Phase 1 clinical trial in men with metastatic castration-resistant prostate cancer (mCRPC), which is expected to start later this year. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-29 | Arnatar Therapeutics, Inc. | Arnatar Therapeutics Presents Clinical Data from Healthy Volunteers at the American College of Cardiology Annual Scientific Session (ACC.26) arnatar.com ↗ |
| 2025-12-02 | Archeus Technologies, Inc. | Archeus Technologies Doses First Patient with ART-101 in Phase 1 Prostate Cancer Study archeustech.com ↗ |
| 2025-07-29 | Eckert & Ziegler Radiopharma GmbH | Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101 ezag.com ↗ |
| 2025-06-20 | Archeus Technologies, Inc. | Archeus Technologies Receives FDA Clearance of Investigational New Drug Application for ART-101 in Development for the Treatment of Prostate Cancer archeustech.com ↗ |
| 2025-05-28 | Archeus Technologies, Inc. | Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer archeustech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART101 | “A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects” NCT07529600 ↗ |
| Known as | ART101 Injection | “A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects” NCT07529600 ↗ |
| Route | Subcutaneous | “administered via subcutaneous injection” NCT06780033 ↗ |